Denver’s Channel 7 News, KMGH, ran a story and a short video interview with CEO Mark Spiecker.
Sharklet’s technology could keep dirty devices from making us sick, but it’s not just smartphone surfaces that could benefit.
“In hospitals right now, about 2 million a year get what are called hospital acquired infections. We spend about $30 billion a year treating those,” says Spiecker. “About 100,000 people die a year.”
Last year, Research Scientist Dr. Ethan Mann published a massive study on the performance of Sharklet against competitor anti-microbial technologies. Many outlets picked up on this study, including the Washington Post.
In experiments designed to mimic the transmission of bacteria via both touch and sneezes, the researchers found that Sharklet was more effective than copper, which is one of the most popular anti-microbial surfaces for hospital use. While copper harbored 80 percent less MRSA — antibiotic resistant bacteria — than control surfaces, Sharklet showed reductions of as much as 94 percent.
InnovatioNews published another profile about Sharklet and the company’s expected growth. Be sure to scroll to the bottom of the article to see an interview with our CEO, Mark Spiecker, where he talks about the company at the Rocky Mountain Life Science Investor & Partnering Conference.
“So much of our technology uses chemicals or heavy metals to prevent bacterial growth,” says Mark Spiecker, who joined the company in 2008 and took over as CEO in 2010 when it moved to the Bioscience Park Center incubator.
“We don’t need that. With our surface, if the bacteria can’t attach, they don’t have the chance to grow. We come at that problem from an entirely new angle.”
Regional manufacturing publication Company Week dropped by Sharklet to do a profile of the company and our upcoming products.
“There’s a significant market for iPhone cases,” explains Sharklet CEO Mark Spiecker. “Everybody knows what an iPhone case is, and when I walk into a meeting and show him or her our technology it’s a very tangible thing,” he says. He shows the data on how the case repels bacteria based on Sharklet’s patented technologies. Hence a company focused on medical devices and planning to debut its first products this year is starting out with an iPhone case under $30.
Microsoft’s Work blog wrote a profile about biomimicry and Sharklet.
Today, businesses are looking at how nature works to find solutions for human problems. This emergent field is called “biomimicry,” from the Greek bios (life) and mimesis (imitation). In business, biomimicry means innovations inspired by nature, and so far, the greatest business advances in biomimicry have been design oriented. However, Mother Nature is also the Master Organizer of things. Perhaps it’s time to consider her opinion on the way we organize our lives and businesses.
Platelet adhesion and activation are key events in thrombus or clot formation on blood-contacting biomaterials. Thus understanding the complex interactions between biomaterial surface properties and platelets is important for developing vascular access devices that limit thromboembolic events. Medical-grade poly(urethanes) are frequently used in blood-contacting medical devices due to their desirable mechanical properties and high level of hemocompatibility. Moreover, it has been shown that sub-platelet-sized micropatterns reduce platelet adhesion. Based on this evidence, we hypothesized that bio-inspired, antifouling Sharklet™ (SK) microtopographies replicated in biomedical thermoplastic poly(urethane) (TPU) reduce both platelet adhesion and activation compared to smooth (SM) controls.
Ventilator-associated pneumonia (VAP) is a leading hospital acquired infection in intensive care units despite improved patient care practices and advancements in endotracheal tube (ETT) designs. The ETT provides a conduit for bacterial access to the lower respiratory tract and a substratum for biofilm formation, both of which lead to VAP. A novel microscopic ordered surface topography, the Sharklet micro-pattern, has been shown to decrease surface attachment of numerous microorganisms, and may provide an alternative strategy for VAP prevention if included on the surface of an ETT. To evaluate the feasibility of this micro-pattern for this application, the microbial range of performance was investigated in addition to biofilm studies with and without a mucin-rich medium to simulate the tracheal environment in vitro.